Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Regulation FD Disclosure

On September 20, 2018, Array BioPharma Inc. issued a press release announcing that the European Commission (EC) has approved BRAFTOVI^® in combination with MEKTOVI^® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF^V600 mutation, as detected by a validated test. This approval is applicable to all 28 European Union (EU) member states, as well as Liechtenstein, Iceland and Norway. A copy of the press release is included as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

(d)Exhibits

ARRAY BIOPHARMA INC ExhibitEX-99.1 2 a9202018euapproval.htm EXHIBIT 99.1 a9202018euapproval News Release European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma – European Commission approval applies to all 28 European Union member states,…To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.